<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091426</url>
  </required_header>
  <id_info>
    <org_study_id>CLS001-CO-PR-014</org_study_id>
    <secondary_id>2016-003849-28</secondary_id>
    <nct_id>NCT03091426</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacodynamics, Safety, Tolerability and Efficacy of Omiganan BID in Patients With Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutanea Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutanea Life Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has a randomized, double-blind, placebo-controlled design to assess the efficacy,
      pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic
      dermatitis when applied BID to all atopic dermatitis lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">December 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Evaluation (oSCORAD)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>oSCORAD Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Evaluation (EASI)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>EASI Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Evaluation (IGA)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>IGA Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-Orientated Outcome Measure (POEM)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Patient Assessment by collecting POEM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Assessment of health-related quality of life by measuring DLQI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eDiary</measure>
    <time_frame>Within 4 Weeks</time_frame>
    <description>Singe-Question assessment of pruritus and sleeplessness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Photography</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Whole body photograph for qualitative and observational record</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Biomarkers)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Local biomarkers sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Microbiome)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Microbiome analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Microbiology)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Microbiology analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (TEWL)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Transepidermal water-loss assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Thermography)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Skin temperature measurements will be taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (TAP)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Analysis of biomarkers captured by Transdermal Analysis Patch</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (Cytokines)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Cytokine assessment via blood evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (AE)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Adverse Events will be collected throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Vital Signs)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Vital Signs will be collected throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Clinical Laboratory Tests)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>Lab samples collected in various timepoints within the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (ECG)</measure>
    <time_frame>Within 7 Weeks</time_frame>
    <description>ECGs collected before beginning and end of study</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Omiganan 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omiganan 1.75%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omiganan 2.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omiganan</intervention_name>
    <description>Omiganan 1%</description>
    <arm_group_label>Omiganan 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omiganan</intervention_name>
    <description>Omiganan 1.75%</description>
    <arm_group_label>Omiganan 1.75%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omiganan</intervention_name>
    <description>Omiganan 2.5%</description>
    <arm_group_label>Omiganan 2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with mild to moderate AD (IGA 2 or 3) 18 to 65 years of
             age,inclusive. The health status is verified by absence of evidence of any clinical
             significant active or uncontrolled chronic disease other than AD following a detailed
             medical history, a complete physical examination including vital signs, 12-lead ECG,
             hematology, blood chemistry, virology and urinalysis;

          -  Confirmed AD diagnosis;

          -  Symptoms present for at least 1 year;

          -  EASI between 7.1 - 50.0, inclusive at screening;

          -  2-20% body surface area (BSA) affected at screening;

          -  Body mass index (BMI) between 18 and 35 kg/m2, inclusive, and with a minimum weight of
             50 kg;

          -  Able to participate and willing to give written informed consent and to comply with
             the study restrictions;

          -  Subjects and their partners of childbearing potential must use effective
             contraception, for the duration of the study and for 3 months after the last dose.

        Exclusion Criteria:

          -  Any current and / or recurrent clinical significant skin condition other than AD;

          -  Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding;

          -  Ongoing use of prohibited atopic dermatitis treatments. Requires washout period prior
             to baseline (first dose of the study drug);

          -  Use of topical medication (prescription or over-the-counter [OTC]) within 14 days of
             study drug administration, or less than 5 half-lives (whichever is longer) in local
             treatment area;

          -  Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of
             enrollment;

          -  Known hypersensitivity to the compound or excipients of the compound or known
             hypersensitivity to one or more different emollients;

          -  Participation in an investigational drug or device study within 3 months prior to
             screening or more than 4 times a year;

          -  Loss or donation of blood over 500 mL within three months (males) or four months
             (females) prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. (Koos) Burggraaf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Human Drug Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LUMC/Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

